Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
KALA 
Kala Pharmaceuticals Inc (KALA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
10/30/2025: KALA (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $1.5
1 Year Target Price $1.5
| 1 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -69.92% | Avg. Invested days 32 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 5.61M USD | Price to earnings Ratio - | 1Y Target Price 1.5 |
Price to earnings Ratio - | 1Y Target Price 1.5 | ||
Volume (30-day avg) 2 | Beta -2.11 | 52 Weeks Range 0.75 - 20.60 | Updated Date 10/30/2025 |
52 Weeks Range 0.75 - 20.60 | Updated Date 10/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -5.96 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -51.9% | Return on Equity (TTM) -708.34% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 8800401 | Price to Sales(TTM) 1.16 |
Enterprise Value 8800401 | Price to Sales(TTM) 1.16 | ||
Enterprise Value to Revenue 0.04 | Enterprise Value to EBITDA -0.16 | Shares Outstanding 7021040 | Shares Floating 5349050 |
Shares Outstanding 7021040 | Shares Floating 5349050 | ||
Percent Insiders 2.17 | Percent Institutions 49.18 |
Upturn AI SWOT
Kala Pharmaceuticals Inc
Company Overview
History and Background
Kala Pharmaceuticals, Inc. was founded in 2009. It focused on developing therapies for eye diseases using its proprietary mucus-penetrating particle (MPP) technology. Due to struggles commercializing their lead products, the company underwent significant restructuring.
Core Business Areas
- Ophthalmology: Historically, Kala focused on developing and commercializing therapies for ocular surface diseases. However, given the strategic restructuring, the focus may have shifted.
Leadership and Structure
Details on the current leadership team and structure would need to be gathered from recent filings after the restructuring.
Top Products and Market Share
Key Offerings
- Eysuvis: Eysuvis is a corticosteroid indicated for the short-term (up to two weeks) treatment of signs and symptoms of dry eye disease. Market share data is difficult to obtain due to changing focus of the company. Competitors include Restasis (AGN), Xiidra (NOVN).
- Inveltys: Inveltys is a corticosteroid indicated for the treatment of post-operative inflammation and pain following ocular surgery. Market share data is difficult to obtain due to changing focus of the company. Competitors include Lotemax (BAX), Durezol (ALC).
Market Dynamics
Industry Overview
The ophthalmology market is driven by aging populations, increased prevalence of eye diseases, and technological advancements. Dry eye disease and post-operative inflammation are significant segments.
Positioning
Kala's positioning was based on its MPP technology. The current positioning requires re-evaluation due to restructuring.
Total Addressable Market (TAM)
The global ophthalmology market is estimated to be hundreds of billions of dollars. Kala's TAM within this larger market depends on their marketed products and pipeline. The TAM would need to be determined from industry reports which is unavailable at this time.
Upturn SWOT Analysis
Strengths
- MPP Technology (potentially, if still utilized)
- Approved Products (Eysuvis, Inveltys - value depends on commercial success)
- Potential for Pipeline Development (if continuing research)
Weaknesses
- Commercialization Challenges
- Financial Instability (potentially after restructuring)
- Limited Pipeline Depth
- Small Market Share
Opportunities
- Strategic Partnerships
- New Product Development
- Expansion into New Markets
- Acquisition by a Larger Company
Threats
- Competition from Established Players
- Generic Entry
- Regulatory Changes
- Economic Downturn
Competitors and Market Share
Key Competitors
- AGN
- NOVN
- BAX
- ALC
Competitive Landscape
Kala Pharmaceuticals faced significant disadvantages compared to its competitors due to limited resources and market access. Restructuring might change this
Growth Trajectory and Initiatives
Historical Growth: Historical growth was limited due to commercialization challenges. Revenues from products were not sufficient to be profitable.
Future Projections: Future projections are difficult to estimate without more information about the restructured company's plans. Analyst estimates would be needed.
Recent Initiatives: Recent initiatives would include restructuring efforts and potential strategic changes.
Summary
Kala Pharmaceuticals has faced considerable challenges, particularly regarding the commercialization of its approved products, leading to significant restructuring. Its MPP technology holds potential, but its market share is small, and it struggles against larger competitors. Future success depends on the restructured company's ability to forge strategic partnerships, improve its product pipeline, and effectively market its existing products. Given its history, the company needs to be very careful about how it plans the company's next steps.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company SEC Filings
- Company Website
- Industry Reports
Disclaimers:
This analysis is based on publicly available information and may not reflect the most up-to-date details regarding the company's restructuring. Market share estimates are approximate. This is not investment advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Kala Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Arlington, MA, United States | ||
IPO Launch date 2017-07-20 | CEO - | ||
Sector Healthcare | Industry Biotechnology | Full time employees 38 | Website https://www.kalarx.com |
Full time employees 38 | Website https://www.kalarx.com | ||
KALA BIO, Inc. a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of therapies for rare and severe eye diseases. The company's lead product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects; and limbal stem cell deficiency and other rare corneal diseases. Its preclinical development product consists of KPI-014 for the treatment of rare inherited retinal diseases. The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023. KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.